Growth Problems in Children Following Cancer Treatment
Medically reviewed by C.H. Weaver MD Medical Editor (08/2018)
Problems with growth are caused by damage to the pituitary system, also known as the hormone system. Chemotherapy and radiation to the brain (cranial radiation) can damage the sensitive organs that comprise this system, resulting in lower than normal levels of essential hormones such as growth hormone and thyroid hormone. Early diagnosis and treatment with hormone replacement will help assure that survivors of childhood cancers reach their optimal height and healthy body weigh
What are growth problems
Common growth problems include reduced height and/or metabolism problems that result in obesity and reduced lean muscle.
What causes growth problems
A common cause of growth problems in survivors of childhood cancers is their past treatment for cancer. Chemotherapy and radiation can cause damage to the endocrine or hormone system, which is comprised of many organs that release hormones into the body, including the thyroid, pituitary, and adrenal gland. Hormones are chemical substances that control the activity of certain cells in the body. The most commonly known hormones are the sex hormones, estrogen and testosterone; however; there are many other hormones that serve a variety of functions in the body. For example, the pituitary gland in the brain releases growth hormone which stimulates growth in all parts of the body, and the thyroid gland in the neck releases thyroid hormone, which increases metabolism.
The cancer treatments that are most likely to damage the endocrine system are cranial radiation and chemotherapy. Chemotherapy with cranial radiation and chemotherapy alone are known to cause obesity even after patients treated for childhood ALL have attained their final height. Also, a lower than predicted final height occurs in patients treated with cranial radiation or the combination of chemotherapy and cranial radiation. 
What are the symptoms of damage to the endocrine system
Long-term survivors of childhood cancer are likely to experience growth hormone deficiency resulting in: ,,
- Lower than predicted height.
- Obesity (increased fat mass).
- Reduced strength (reduced lean mass).
- Reduced exercise tolerance.
- Low bone density.
- Problems with progression of puberty.
- Azoospermia in males (no sperm).
- Lower quality of life.
- Lower academic achievement.
What can be done to prevent growth problems
Early diagnosis and treatment will help ensure that patients reach their optimum growth potential. Also, the use of multiagent chemotherapy and lower radiation doses and volumes has decreased the long-term side effects of treatment for children with Hodgkin’s disease. These approaches, aimed at reducing the risk of long-term growth problems, are also being evaluated in children with ALL.
How are growth problems treated
Treatment for growth problems may consist of administration of the hormones that are deficient, such as growth hormone, thyroid hormone, or sex hormones. A common treatment for children that have undergone treatment for cancer is regular injections of human growth hormone to treat a deficiency of this naturally occurring hormone. Some children receive daily injections, while others receive injections several times a week. Treatment usually lasts several years, although results are often seen as soon as three to four months after the injections are started. The earlier the treatment for growth hormone deficiency is started, the better chance the child will have of attaining normal or near-normal adult height.
 Birkebaek NH, Clausen N. Height and weight pattern up to 20 years after treatment for acute lymphoblastic leukaemia. Arch Dis Child. 1998 Aug;79(2):161-4.
 Murray RD, Brennan BM, Rahim A, Shalet SM. Survivors of childhood cancer: long-term endocrine and metabolic problems dwarf the growth disturbance.Acta Paediatr Suppl. 1999 Dec;88(433):5-12.
 Murray RD, Brennan BM, Rahim A, Shalet SM. Survivors of childhood cancer: long-term endocrine and metabolic problems dwarf the growth disturbance. Acta Paediatr Suppl. 1999 Dec;88(433):5-12.
 Brougham MF, Kelnar CJ, Wallace WH. The late endocrine effects of childhood cancer treatment. Pediatr Rehabil. 2002 Oct-Dec;5(4):191-201.
 Sklar CA. Growth and neuroendocrine dysfunction following therapy for childhood cancer. Pediatr Clin North Am. 1997 Apr;44(2):489-503.
 Langebrake C, Reinhardt D, Ritter J, Minimising the long-term adverse effects of childhood leukaemia therapy. Drug Saf. 2002;25:1057-77.